TITLE

Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes

AUTHOR(S)
Hollander, Priscilla A.; Blonde, Lawrence; Rowe, Richard; Mehta, Adi E.; Milburn, Joseph L.; Hershon, Kenneth S.; Chiasson, Jean-Louis; Levin, Seymour R.
PUB. DATE
October 2004
SOURCE
Diabetes Care;Oct2004, Vol. 27 Issue 10, p2356
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE -- Glycemic control using inhaled, dry-powder insulin plus a single injection of long-acting insulin was compared with a conventional regimen in patients with type 2 diabetes, which was previously managed with at least two daily insulin injections. RESEARCH DESIGN AND METHODS -- Patients were randomized to 6 months' treatment with either premeal inhaled insulin plus a bedtime dose of Ultralente (n = 149) or at least two daily injections of subcutaneous insulin (mixed regular/NPH insulin; n = 150). The primary efficacy end point was the change in HbA[sub1c] from baseline to the end of study. RESULTS -- HbA[sub1c] decreased similarly in the inhaled (-0.7%) and subcutaneous (-0.6%) insulin groups (adjusted treatment group difference: -0.07%, 95% CI -0.32 to 0.17). HbA[sub1c] <7.0% was achieved in more patients receiving inhaled (46.9%) than subcutaneous (31.7%) insulin (odds ratio 2.27, 95% CI 1.24-4.14). Overall hypoglycemia (events per subject-month) was slightly lower in the inhaled (1.4 events) than in the subcutaneous (1.6 events) insulin group (risk ratio 0.89, 95% CI 0.82-0.97), with no difference in severe events. Other adverse events, with the exception of increased cough in the inhaled insulin group, were similar. No difference in pulmonary function testing was seen. Further studies are underway to assess tolerability in the longer term. Insulin antibody binding increased more in the inhaled insulin group. Treatment satisfaction was greater in the inhaled insulin group. CONCLUSIONS -- Inhaled insulin appears to be effective, well tolerated, and well accepted in patients with type 2 diabetes and provides glycemic control comparable to a conventional subcutaneous regimen.
ACCESSION #
14704888

 

Related Articles

  • Insulin. Jordan, Sue; Lake, Richard // Nursing Standard;4/20/2005, Vol. 19 Issue 32, Following p96 

    Discusses information about insulin, which is prescribed to compensate for the failure of the pancreas that occurs in diabetes mellitus. Administration; Drug interactions; Cautions; Hypoglycemia.

  • Apidra Now on Pharmacy Shelves. Trecroci, D. // Diabetes Health;May2006, Vol. 15 Issue 5, p17 

    Announces that sanofi-aventis' fast-acting Apidra (insulin glulisine [rDNA origin] injection) is now available by prescription in the U.S. on February 28, 2006 and was granted approval by the U.S. Food & Drug Administration in April 2004. Regimens to which Apidra should be used include a...

  • New Options in Insulin Therapy. SARAIYA, NIDHI; MARTIN, SPENCER T. // Connecticut Medicine;Oct2015, Vol. 79 Issue 9, p553 

    The article presents a study on the options of using insulin therapy for the treatment of type 1 diabetes mellitus (TlDM) and type 2 diabetes mellitus (T2DM). Topics discussed include the approval of the insulin glargine 300 units/mL formulation by the U.S. Food and Drug Administration (FDA),...

  • Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Hanaire-Broutin, Helene; Melki, Vincent; Bessiees-Lacombe, Sylvie; Tauber, Jean-Pierre; Hanaire-Broutin, H; Melki, V; Bessières-Lacombe, S; Tauber, J P // Diabetes Care;Sep2000, Vol. 23 Issue 9, p1232 

    Objective: To compare the efficacy of 2 intensified insulin regimens, continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI), by using the short-acting insulin analog lispro in type 1 diabetic patients.Research Design and Methods: A total of...

  • Review: Intensive insulin therapy increases risk for hypoglycemia but not mortality in critically ill adults. Kovalaske, Michelle A.; Gandhi, Gunjan Y.; Griesdale, D. E. // ACP Journal Club;8/18/2009, Vol. 151 Issue 2, p2 

    The article reports that in critically ill adults, intensive insulin therapy increases risk for hypoglycemia but does not reduce overall mortality. Meta-analysis showed that intensive insulin therapy was not associated with reduced mortality but increased risk for hypoglycemic events....

  • Intensive glucose control increased risk for death and severe hypoglycemia in critically ill adults. Kovalaske, Michelle A.; Gandhi, Gunjan Y.; Finfer, S. // ACP Journal Club;8/18/2009, Vol. 151 Issue 2, p3 

    The article reports that in critically ill adults, intensive insulin therapy increases risk for hypoglycemia but does not reduce overall mortality. Meta-analysis showed that intensive insulin therapy was not associated with reduced mortality but increased risk for hypoglycemic events....

  • Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. Sang Won Suh; Gum, Elizabeth T.; Hamby, Aaron M.; Chan, Pak H.; Swanson, Raymond A. // Journal of Clinical Investigation;Apr2007, Vol. 117 Issue 4, p910 

    Hypoglycemic coma and brain injury are potential complications of insulin therapy. Certain neurons in the hippocampus and cerebral cortex are uniquely vulnerable to hypoglycemic cell death, and oxidative stress is a key event in this cell death process. Here we show that hypoglycemia-induced...

  • Long-Term Intensive Treatment of Type 1 Diabetes With the Short-Acting Insulin Analog Lispro in Variable Combination With NPH Insulin at Mealtime. Lalli, Carlo; Ciofetta, Marco; Del Sindaco, Paola; Torlone, Elisabetta; Pampanelli, Simeone; Compagnucci, Pietro; Cartechini, Maria Giululia; Bartocci, Linda; Brunetti, Paolo; Bolli, Geremia B. // Diabetes Care;Mar1999, Vol. 22 Issue 3, p468 

    Presents a study which established whether the short-acting insulin analog lispro can be successfully implemented in long-term intensive insulin therapy in type 1 diabetes, and the effects on glycemic control and frequency and awareness of hypoglycemia. Research design and methods; Results;...

  • Advances in Insulin Injection Research Influences Patient Adherence. Aronson, Ronnie; Bailey, Timothy; Hirsch, Laurence; Saltiel-Berzin, Rita // U.S. Endocrinology;Winter2013, Vol. 9 Issue 2, p114 

    Insulin formulations and injection devices have improved dramatically since the first insulin injection was given in 1922. Adherence to insulin therapy, however, is estimated at 62-64 % despite research indicating that good glycemic control improves patient outcomes. The challenge is to improve...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics